Luciano Adorini (L Adorini)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Replacement Therapy

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Luciano Adorini, Kristoffer Rigbolt, Michael Feigh, Jonathan Roth, Mary Erickson
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PloS one 19 (4) (2024)
Luciano Adorini, Kristoffer Rigbolt, Michael Feigh, Jonathan Roth, Mary Erickson
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PloS one 19 (4) (2024)
Luciano Adorini, Kristoffer Rigbolt, Michael Feigh, Jonathan Roth, Mary Erickson
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PloS one 19 (4) (2024)
Justine Gillard, Corinne Picalausa, Christoph Ullmer, Luciano Adorini, Bart Staels, Anne Tailleux, Isabelle A Leclercq
Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients 14 (13) (2022)
Di Matteo Sabina, Lorenzo Nevi, D Costantini, Diletta Overi, G Carpino, S Safarikia, F Giulitti, C Napoletano, E Manzi, A M De Rose, F Melandro, M Bragazzi, P B Berloco, F Giuliante, Gian Luca Grazi, A Giorgi, V Cardinale, Luciano Adorini, E Gaudio, D Alvaro
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. PloS one 14 (1) (2019)